Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fabienne Brilot

Showing results (111-120 of 128) with videos related to

Pageof 13
Sort By:
Neurology(R) Neuroimmunology & Neuroinflammation|February 7, 2020
International multicenter examination of MOG antibody assaysMarkus Reindl, Kathrin Schanda, Mark Woodhall, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2024
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated diseaseGanesha Liyanage, Benjamin P Trewin, Joseph A Lopez, et al.
Neurology|December 16, 2022
Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter StudySara Carta, Álvaro Cobo Calvo, Thaís Armangué, et al.
Acta Neuropathologica Communications|September 5, 2019
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelinationFiona Tea, Joseph A Lopez, Sudarshini Ramanathan, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|October 15, 2025
Treatment response in children with relapsing MOG-antibody associated diseaseEva-Maria Wendel, John J Chen, Annikki Bertolini, et al.
Cell Reports. Medicine|March 22, 2021
Long-term persistence of RBD<sup>+</sup> memory B cells encoding neutralizing antibodies in SARS-CoV-2 infectionArunasingam Abayasingam, Harikrishnan Balachandran, David Agapiou, et al.
Frontiers in Immunology|December 22, 2022
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cellsChansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, et al.
Plos Medicine|July 6, 2021
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsFiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 22, 2025
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of ProtectionAvani Yeola, Samuel Houston, Anupriya Aggarwal, et al.
Ebiomedicine|November 16, 2024
Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemicAnouschka Akerman, Christina Fichter, Vanessa Milogiannakis, et al.
Pageof 13

Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
Neurology(R) Neuroimmunology & Neuroinflammation|February 7, 2020
International multicenter examination of MOG antibody assaysMarkus Reindl, Kathrin Schanda, Mark Woodhall, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|January 30, 2024
The MOG antibody non-P42 epitope is predictive of a relapsing course in MOG antibody-associated diseaseGanesha Liyanage, Benjamin P Trewin, Joseph A Lopez, et al.
Neurology|December 16, 2022
Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter StudySara Carta, Álvaro Cobo Calvo, Thaís Armangué, et al.
Acta Neuropathologica Communications|September 5, 2019
Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelinationFiona Tea, Joseph A Lopez, Sudarshini Ramanathan, et al.
European Journal of Paediatric Neurology : EJPN : Official Journal of the European Paediatric Neurology Society|October 15, 2025
Treatment response in children with relapsing MOG-antibody associated diseaseEva-Maria Wendel, John J Chen, Annikki Bertolini, et al.
Cell Reports. Medicine|March 22, 2021
Long-term persistence of RBD<sup>+</sup> memory B cells encoding neutralizing antibodies in SARS-CoV-2 infectionArunasingam Abayasingam, Harikrishnan Balachandran, David Agapiou, et al.
Frontiers in Immunology|December 22, 2022
High titre neutralizing antibodies in response to SARS-CoV-2 infection require RBD-specific CD4 T cells that include proliferative memory cellsChansavath Phetsouphanh, Weng Hua Khoo, Katherine Jackson, et al.
Plos Medicine|July 6, 2021
SARS-CoV-2 neutralizing antibodies: Longevity, breadth, and evasion by emerging viral variantsFiona Tea, Alberto Ospina Stella, Anupriya Aggarwal, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 22, 2025
COVID-19 Vaccine Boosters in People With Multiple Sclerosis: Improved SARS-CoV-2 Cross-Variant Antibody Response and Prediction of ProtectionAvani Yeola, Samuel Houston, Anupriya Aggarwal, et al.
Ebiomedicine|November 16, 2024
Cross-sectional and longitudinal genotype to phenotype surveillance of SARS-CoV-2 variants over the first four years of the COVID-19 pandemicAnouschka Akerman, Christina Fichter, Vanessa Milogiannakis, et al.
Pageof 13